Free Trial
NASDAQ:ALLR

Allarity Therapeutics (ALLR) Stock Price, News & Analysis

Allarity Therapeutics logo
$0.94 +0.07 (+7.46%)
Closing price 04:00 PM Eastern
Extended Trading
$0.95 +0.00 (+0.25%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Allarity Therapeutics Stock (NASDAQ:ALLR)

Key Stats

Today's Range
$0.87
$0.96
50-Day Range
$0.80
$1.13
52-Week Range
$0.61
$6.00
Volume
317,510 shs
Average Volume
1.47 million shs
Market Capitalization
$13.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Allarity Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

ALLR MarketRank™: 

Allarity Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 439th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Allarity Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Allarity Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Allarity Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Allarity Therapeutics are expected to grow in the coming year, from ($78.08) to ($46.85) per share.

  • Price to Book Value per Share Ratio

    Allarity Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.92% of the float of Allarity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Allarity Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Allarity Therapeutics has recently decreased by 19.79%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Allarity Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Allarity Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.92% of the float of Allarity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Allarity Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Allarity Therapeutics has recently decreased by 19.79%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Allarity Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Allarity Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for ALLR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Allarity Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.08% of the stock of Allarity Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 11.53% of the stock of Allarity Therapeutics is held by institutions.

  • Read more about Allarity Therapeutics' insider trading history.
Receive ALLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLR Stock News Headlines

Allarity Therapeutics Delays 10-Q Filing
Elon Musk’s New Technology
Elon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.tc pixel
See More Headlines

ALLR Stock Analysis - Frequently Asked Questions

Allarity Therapeutics' stock was trading at $1.17 on January 1st, 2025. Since then, ALLR stock has decreased by 19.3% and is now trading at $0.9446.

Allarity Therapeutics, Inc. (NASDAQ:ALLR) released its quarterly earnings results on Friday, August, 15th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.06.

Shares of Allarity Therapeutics reverse split on Wednesday, September 11th 2024.The 1-30 reverse split was announced on Wednesday, September 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Allarity Therapeutics' board authorized a stock buyback plan on Monday, March 3rd 2025, which allows the company to buy back $5,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 128.1% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its shares are undervalued.

Top institutional investors of Allarity Therapeutics include XTX Topco Ltd (0.34%), Geode Capital Management LLC (0.34%) and Jane Street Group LLC (0.17%).

Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allarity Therapeutics investors own include AMC Entertainment (AMC), Plug Power (PLUG), Adial Pharmaceuticals (ADIL), Cara Therapeutics (CARA), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH) and Nuwellis (NUWE).

Company Calendar

Last Earnings
8/15/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALLR
CIK
1860657
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$9.00
Potential Upside/Downside
+856.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.51 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-173.31%
Return on Assets
-102.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.31
Quick Ratio
2.66

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.83 per share
Price / Book
1.13

Miscellaneous

Outstanding Shares
14,620,000
Free Float
14,608,000
Market Cap
$13.76 million
Optionable
Not Optionable
Beta
0.08
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:ALLR) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners